Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis Makes The Case For Early Filing Of Cabozantinib In Frontline Kidney Cancer

Executive Summary

Company recruited clinical experts to explain why Phase II CABOSUN should be enough for approval and why a Phase III study is now impractical.

You may also be interested in...



Takeda Adds Exelixis Arrow To Oncology Quiver

Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.

Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market

One of a trio of new drugs shaking up the kidney cancer market, Cabometyx (cabozantinib) does better than expected in its first nine weeks on the US market, and additional indications are on the near horizon.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel